EPS for Gemphire Therapeutics Inc. (GEMP) Expected At $-0.57

July 14, 2018 - By Duane Lopez

Analysts expect Gemphire Therapeutics Inc. (NASDAQ:GEMP) to report $-0.57 EPS on August, 13.They anticipate $0.17 EPS change or 22.97 % from last quarter’s $-0.74 EPS. After having $-0.58 EPS previously, Gemphire Therapeutics Inc.’s analysts see -1.72 % EPS growth. The stock increased 1.78% or $0.14 during the last trading session, reaching $8.01. About 329,086 shares traded. Gemphire Therapeutics Inc. (NASDAQ:GEMP) has declined 37.19% since July 14, 2017 and is downtrending. It has underperformed by 49.76% the S&P500.

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease and nonalcoholic fatty liver disease/non-alcoholic steatohepatitis . The company has market cap of $114.00 million. It is developing gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy and for those patients who present with NASH. It currently has negative earnings.

More notable recent Gemphire Therapeutics Inc. (NASDAQ:GEMP) news were published by: Seekingalpha.com which released: “Gemphire’s Positive Phase 2b Results Reignites The NASH Market Yet Again” on July 02, 2018, also Nasdaq.com with their article: “Mid-Day Market Update: Crude Oil Up Over 1%; Gemphire Therapeutics Shares Spike Higher” published on June 29, 2018, Benzinga.com published: “Benzinga Pro’s 5 Stocks To Watch Today” on June 29, 2018. More interesting news about Gemphire Therapeutics Inc. (NASDAQ:GEMP) were released by: Streetinsider.com and their article: “After-Hours Stock Movers 06/28: (GEMP) (NKE) (VRTX) Higher; (SNX) (CVG) Lower (more…)” published on June 28, 2018 as well as Streetinsider.com‘s news article titled: “Gemphire (GEMP) Says Gemcabene Met Primary Endpoint in INDIGO-1 Study of Severe Hypertriglyceridemia” with publication date: June 28, 2018.

Gemphire Therapeutics Inc. (NASDAQ:GEMP) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: